Boron neutron capture therapy (BNCT) for malignant melanoma with special reference to absorbed doses to the normal skin and tumor

Australasian Physical and Engineering Sciences in Medicine

Volumn 26, Issue 3, 2003, Pages 97-103

  Fukuda, H ^a   Hiratsuka, J ^b   Kobayashi, T ^c   Sakurai, Y ^c   Yoshino, K ^d   Karashima, H ^e   Turu, K ^f   Araki, K ^f   Mishima, Y ^g   Ichihashi, M ^f  

^a TOHOKU UNIVERSITY   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d SHINSHU UNIVERSITY   (Japan)

^e MITSUBISHI ELECTRIC CORPORATION   (Japan)

^f KOBE UNIVERSITY   (Japan)

^g Mishima Institute for Dermatol Res   (Japan)

Author keywords

Absorbed dose; BNCT; BPA; Dose optimization; Dosimetry; Melanoma

Indexed keywords

DOSIMETRY; IRRADIATION; PATIENT TREATMENT; PHARMACOKINETICS; RADIATION; SKIN; TUMORS;

MALIGNANT MELANOMA;

BORON;

4 BORONOPHENYLALANINE B 10; GOLD; MAGNESIUM DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE CALCULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; FOIL; GAMMA RADIATION; GUIDE WIRE; HUMAN; IRRADIATION; LIGHT EMITTING DIODE; MAXIMUM TOLERATED DOSE; MELANOMA; NEUTRON CAPTURE THERAPY; NEUTRON DOSIMETRY; NEUTRON RADIATION; OPTIMAL DRUG DOSE; RADIATION ABSORPTION; RADIATION DOSE DISTRIBUTION; SKIN; SKIN GRAFT; SKIN INJURY; SKIN NECROSIS; SKIN ULCER; TREATMENT PLANNING;

EID: 10744226723     PISSN: 01589938     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03178777     Document Type: Article

References (21)

1. Hawthorne, M. F. The role of chemistry in the development of boron neutron capoture therapy of cancer, Angew Chem Int Ed Engl 32:950-984, 1993.
2. 10B-chlorpromazine, Pigment Cell Res 1:215-221, 1973.
3. 10B-compound, Lancet 12:383-389, 1989.
4. Mishima, Y. Selective thermal neutron capture therapy of cancer cells using their specific metabolic activities-melanoma as prototype, In: Mishima Y, ed. Cancer Neutron Capture Therapy, New York, London, Plenum Press, 1-26, 1996.
5. Yoshino, K., Suzuki, K., Mori, Y., et al. Improvement of solubility of p-boronophenylalanine by complex formation with monosaccharides. Strahlenther Oncol, 165:127-129, 1989.
6. 10B concentration in tissue for neutron capture therapy by prompt gamma-ray spectrometry, Nucl Inst Method 204:525-531, 1982.
7. Overgaard, J. The role of radiotherapy in recurrent and metastatic malignant melanomas: A clinical radiobiological study, Int J Radiat Oncol Biol Phys 12, 867-872, 1986.
8. Douglas, B. G. Implication of the quadratic cell survival curve and human skin radiation "tolerance dose" on fractionation and superfractionation dose selection, Int J Radiat Oncol Biol Phys 8, 1135-1142, 1982.
9. 10B-paraboronophenylalanine with special reference to evaluation of radiation dose and damage to the normal skin, Radiat Res 138:435-442, 1994.
10. Fukuda, H., Mishima, Y., Hiratsuka, J, et al. BNCT of malignant melanoma - Radiobiological analysis and data comparison with conventional radiotherapy. In: Mishima Y, ed. Cancer Neutron Capture Therapy, New York, London: Plenum Press: 663-671, 1996
11. 10B-p-boronophenyl-alanine in tumours, skin and blood of melanoma patients: A study of boron neutron capture therapy for malignant melanoma, Melanoma Res 9:75-83, 1999.
12. Hornsey, S. The relationship between total dose, number of fractions and fraction size in the response of malignant melanoma in patients, Br J Radiol 51:905-909, 1977
13. Overgaard, J. Radiation therapy of malignant melanoma, Int J Radiat Oncol Phys 6:41-44, 1980.
14. Overgaad, J., Overgaard, M., Hansen, P. V., et al. Some factors of importance in the radiation treatment of malignant melanoma, Radiother Oncol 5:183-192, 1986.
15. Hebermalz, H. J., Fisher, J. J. Radiation therapy of malignant melanoma: Experience with high individual treatment doses, Cancer 38:2258-2262, 1976.
16. Konefal, J. B., Emami, B., Pilepich, M. V. Malignant melanoma: Analysis of dose fractionation in radiation therapy, Radiology 164:607-610, 1987.
17. Mackie, R. M., Young, D. Human malignant melanoma, Int J Dermatol 23:433-443, 1984.
18. Bradley, P. D., Rosenfeld, A. B. Tissue equivalence correction for silicon microdosimetry detectors in boron neutron capture therapy, Medical Physics 25:2220-2225, 1998.
19. Imahori, Y., Ueda, S., Ohmori, Y., et al. Fluorine-18-labeled fluoroboronophenylalanine PET in patients with glioma. J Nucl Med 39:325-333, 1998.
20. Kabalka, G. W., Smith, G. T., Reid, W. S., et al. Evaluation of fluorine-18-BPA-fructose for boron neutron capture treatment planning, J Nucl Med 38: 1762-1767, 1997.
21. Kobayashi, T., Sakurai, Y. and Ichikawa, M. A non-invasive dose estimation system for clinical BNCT based on PG-SPECT - Conceptual study and fundamental experiments using HPGe and CdTe semiconductor detectors, Medical Phys 27:2124-2132, 2000.